retatrutide triple agonist glp-1 gip glucagon phase 2 obesity trial First-in-Class 'Triple-G'! Retatrutide, a first-in-class GIP, & hormone receptor drug leads to nearly 29% weight loss in first pivotal test! Eli Lilly announced positive topline results from the Retatrutide Triple Agonist Research Peptide

Transl Psychiatry [Internet]

It is hypothesized that the slowing of gastric emptying contributes to some of the more common adverse events that occur with tirzepatide and selective GLP-1RAs (e.g., nausea, diarrhea, and vomiting), as the incidence of these events most commonly coincides with the timing of the early gastric slowing

If validation fails, the submission should be blocked because site-of-care affects clinical handling and potential vendor/case management routing

Users with specific dietary restrictions beyond what Replenza accommodates should verify ingredient compatibility carefully

Mixed Meal Test and Data Collection Before and 1 year after bariatric surgery ( T = 0 and T = 1, respectively) a 2-h mixed meal test (MMT) was performed

If you can access one medication for 3 months but then need to switch to the other due to cost or availability, having a safe transition protocol makes the alternating inevitable rather than optional